References
- Pottegard A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol 2012; 68:1443–1450.
- McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr 2012; 12:78.
- Geirs DP, Pottegard A, Halldorsson M, Zoega H. A Nationwide Study of Attention-Deficit/Hyperactivity Disorder Drug Use among Adults in Iceland 2003–2012. Basic Clin Pharmacol Toxicol 2014; 1:12243.
- Vejledning om ordination af afhængighedsskabende lægemidler og om substitutionsbehandling af personer med opioidafh ngighed, Danish Helath and Medicines Authority, 2007. http://sundhedsstyrelsen.dk/publ/publ2007/EFT/substitut_ordbehlvejl/afhaengighedlaegemidl.pdf
- National Guideline C. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults Rockville MD: Agency for Healthcare Research and Quality (AHRQ); (12/2/2014).
- Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711.
- Dansk Psykiatrisk Selskab. Retningslinjer for diagnostik og behandling af ADHD hos voksne 2013 (cited 2014, 02–12).
- Produktresume.dk: Danish Health and Medicines Autohrity; [cited 2014 02-12]. .
- Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord 2011; 15:674–683.
- van Wyk GW, Hazell PL, Kohn MR, Granger RE, Walton RJ. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. J Atten Disord 2012; 16:314–324.
- Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67:149–156.
- Forrester MB. Adult atomoxetine ingestions reported to Texas Poison Control Centers, 2003–2005. J Toxicol Environ Health A 2007; 70:1064–1070.
- Lile JA, Stoops WW, Durell TM, Glaser PE, Rush CR. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Exp Clin Psychopharmacol 2006; 14: 136–147.
- Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008; 95:140–146.
- Jensen L, Pagsberg A, Dalhoff K. Methylphenidate misuse in adult patients and the impact of therapeutic use. Hum Exp Toxicol 2014.
- Forrester MB. Adult atomoxetine ingestions reported to Texas Poison Control Centers, 2003–2005. Ann Pharmacother 2006; 40: 2136–2141.
- Medstat.dk [Internet]. State Serum Institute. [cited October 2012].
- Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 2007; 22: 529–536.
- Frauger E, Pauly V, Natali F, Pradel V, Reggio P, Coudert H, et al. Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS drugs 2011; 25:415–424.
- (DLI) DLIAS. Pro.medicin [cited 2014 09–12].
- Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population Neurology 2002; 58:1826–1833.